&w=3840&q=100)
Deepak Fertilisers Q1 results: Profit rises 22% to ₹244 cr on higher sales
The company reported a net profit of ₹199.65 crore in the year-ago period, according to a regulatory filing.
Total revenue rose 16.54 per cent to ₹2,658.75 crore during the June quarter of the 2025-26 fiscal year from ₹2,281.33 crore in a year-ago.
Expenses remained higher at ₹2,337.31 crore as against ₹2,023.25 crore in the said period.
DFPCL Chairman and Managing Director said, "The strong start to FY26 underscores the impact of our strategic transformation and disciplined execution. Our continued focus on specialty products, customer engagement, and operational agility is driving tangible results." The company's net debt further reduced even as "we progressed major capital investments," he said, adding, "This reinforces the strength of our business model." DFPCL manufactures both industrial chemicals and fertilisers with a strong presence in Technical Ammonium Nitrate (mining chemicals), industrial chemicals, and crop nutrition (fertilisers).
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
5 hours ago
- Business Standard
Amid lab-grown rise, Tanishq launches diamond expertise centres
Amid the growing popularity of lab-grown diamonds, jewellery giant Tanishq has launched three new diamond expertise centres in collaboration with the De Beers Group. These centres aim to provide buyers with clarity and transparency, ensuring value to the customer through a technology-backed evaluation system. "There is a lot of confusion caused by the emergence of lab-grown diamonds, and we expect the prices of lab-grown diamonds to keep decreasing as the technology to create them evolves. More customers are now asking if we're selling natural or lab-grown diamonds, and it is this confusion we want to eliminate," said Ajoy Chawla, Chief Executive Officer (CEO) of the jewellery division at Titan Company. Currently, these centres are located in three stores in Bengaluru, but the company plans to expand them to 200 stores in the ongoing financial year (FY26) and eventually roll them out across all 599 stores nationwide. Commenting on gold prices, Chawla told Business Standard that the surge in gold prices has led to ticket-size driven growth, with diamond-studded jewellery also witnessing increased buyer demand. In its quarterly update to the exchanges in early July, the company reported an 18 per cent growth in its jewellery domestic operations for the first quarter (Q1FY26), which was marked by gold price volatility. The company is also observing a shift towards lightweight and lower caratage jewellery among customers. In response, Tanishq has piloted 9-carat gold jewellery under its Mia brand in several coastal markets to assess the impact of humidity. A Mia official told Business Standard earlier this week that the collection, consisting of 25 offerings, will be fully launched before Diwali. Having become a household name over the past 30 years, Tanishq has catered to over 1.3 crore customers to date, with almost 52 lakh purchasing diamond-studded gold jewellery. Speaking about the US tariffs of 25 per cent imposed on Indian exports, Chawla said, "It's too early to react. We should not get carried away, as these tariffs may change over time."
&w=3840&q=100)
Business Standard
8 hours ago
- Business Standard
India's DAP imports from China fall to 97,000 tonnes in July amid new rules
India's import of Di Ammonium Phosphate (DAP) from China has declined sharply and stood at 97,000 tonnes in July this year, Parliament was informed on Friday. DAP is the second most consumed fertiliser after urea in India. Minister of State for Chemicals and Fertilisers Anupriya Patel said DAP import from China declined from approximately 22.28 lakh tonnes in 2023-24 to about 8.47 lakh tonnes in 2024-25 as reported by fertiliser companies. "In July 2025, approximately 0.97 lakh tonnes of DAP have been imported from China," the minister said in a written reply to the Lok Sabha. Phosphatic and Potassic (P&K) fertilisers, including DAP, are under Open General License (OGL). The fertiliser companies are free to import/manufacture these fertilisers as per their business dynamics. Citing reasons for the decline in DAP import, the minister said in October 2021, China amended its catalogue of commodities requiring mandatory additional inspection prior to export of fertiliser-related items, including DAP. The regulatory requirement led to an increase in the CFR (Cost and Freight) price of DAP for India from USD 542 per tonne in April 2024 to approximately USD 800 per tonne in July 2025. The minister said Ammonium Phosphate Sulphate (APS) may serve as a partial alternative to DAP, particularly in sulphur-deficient soils and for sulphur-demanding crops. APS supplies nitrogen, phosphorus, and sulphur, but contains a lower phosphorus content of 20 per cent as compared to 46 per cent in DAP. Thus, APS is a crop- and soil-specific supplement. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
&w=3840&q=100)
Business Standard
9 hours ago
- Business Standard
GSK Pharma Q1 results: PAT rises 12% to ₹279 cr, income declines marginally
GlaxoSmithKline Pharmaceuticals on Friday said its consolidated net profit increased 12 per cent year-on-year to ₹279 crore for the June quarter. The drug firm had reported a net profit of ₹249 crore for the June quarter of the last fiscal. Total income declined marginally to ₹849 crore for the first quarter as compared with ₹850 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a regulatory filing. "GSK continues to invest in its innovative portfolio and is on track to launch the much-awaited oncology assets, Jemperli and Zejula. By launching these assets in India, GSK is addressing a critical unmet need amid a rising cancer burden and limited access to advanced therapies," GlaxoSmithKline Pharmaceuticals MD Bhushan Akshikar said. The company continues to invest in its innovative portfolio and is on track to launch the much-awaited oncology assets, Jemperli and Zejula, he added. By launching these assets in India, GSK is addressing a critical unmet need amid a rising cancer burden and limited access to advanced therapies, Akshikar noted. Jemperli (dostarlimab) is an immuno-oncology treatment for second-line dMMR endometrial cancer and Zejula (niraparib), is a PARP inhibitor indicated for advanced and recurrent ovarian cancer. Shares of the company were trading 8.22 per cent down at ₹2,898.40 apiece on BSE. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
